Tobias Traupe

Tobias Traupe

Auto-generated profile, based on publicly available information

Tobias Traupe

Department of Cardiology, Bern University Hospital, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Hypertension
Verified
Journal Article
Closed access
PDF file
JOJana Ortmann
Jana Ortmann
KAKerstin Amann
Kerstin Amann
MBmed. P Brandes
med. P Brandes
MKMatthias Kretzler
Matthias Kretzler
KMKlaus Münter
Klaus Münter
MBMatthias Barton
Matthias Barton
The cause of focal-segmental glomerulosclerosis as a consequence of physiological aging, which is believed to be inexorable, is unknown. This study investigated whether inhibition of endothelin-1, a growth-promoting peptide contributing to renal injury in hypertension and diabetes, affects established glomerulosclerosis and proteinuria in the aged kidney. We also determined the role of endothelin receptors for podocyte injury in vivo and in vitro. Aged Wistar rats, a model of spontaneous age-dependent glomerulosclerosis, were treated with the orally active endothelin subtype A (ET A ) receptor antagonist darusentan, and evaluation of renal histology, renal function studies, and expression analyses were performed. In vitro experiments using puromycin aminonucleoside to induce podocyte injury investigated the role of ET A receptor signaling for apoptosis, cytoskeletal injury, and DNA synthesis. In aged Wistar rats, established glomerulosclerosis and proteinuria were reduced by >50% after 4 weeks of darusentan treatment, whereas blood pressure, glomerular filtration rate, or tubulo-interstitial renal injury remained unaffected. Improvement of structural injury in glomeruli and podocytes was accompanied by a reduction of the expression of matrix metalloproteinase-9 and p21 Cip1/WAF1 . In vitro experiments blocking ET A receptors using specific antagonists or RNA interference prevented apoptosis and structural damage to podocytes induced by puromycin aminonucleoside. In conclusion, these results support the hypothesis that endogenous endothelin contributes to glomerulosclerosis and proteinuria in the aging kidney. The results further suggest that age-dependent glomerulosclerosis is not merely a “degenerative” but a reversible process locally confined to the glomerulus involving recovery of podocytes from previous injury.

1 November 2002 in Journal Of Hypertension
Verified
Journal Article
Closed access
TTTobias Traupe
Tobias Traupe
MLMatthias Lang
Matthias Lang
WGWinfried Goettsch
Winfried Goettsch
KMKlaus Münter
Klaus Münter
HMHenning Morawietz
Henning Morawietz
MBMatthias Barton
Matthias Barton
Vasoconstrictor prostanoids have been implicated in abnormal vasomotion in atherosclerosis and hypertension. Using lean and diet-induced obese mice, we investigated whether obesity affects vascular function or expression of genes involved in prostanoid action. In lean C57BL/6J mice, at high concentrations acetylcholine caused endothelium-dependent contractions in the carotid artery but not in the aorta. Endothelium-dependent contractions to acetylcholine were blocked by the non-selective cyclooxygenase (COX) inhibitors indomethacin and meclofenamate, or a prostaglandin H2/thromboxane A2 receptor antagonist, but not by inhibitors of COX-2, thromboxane synthase or cytochrome P450 monooxygenase. Obesity increased endothelium-dependent contractions to acetylcholine in the carotid artery, and prostanoid-mediated vasoconstriction was now present in the aorta. Similarly, contractions to endothelin-1 were largely blocked by meclofenamate and were increased in the aorta of obese mice. Real-time quantitative polymerase chain reaction analysis of the thromboxane receptor gene in the carotid artery revealed a robust upregulation in obese animals (18-fold, P < 0.05); in comparison, obesity had a less pronounced effect on thromboxane synthase (2.1-fold increase, P < 0.05), or preproendothelin-1 gene expression (4.2-fold increase, P < 0.05). These data demonstrate that obesity augments prostanoid-dependent vasoconstriction and markedly increases vascular thromboxane receptor gene expression. These changes are likely to promote the development of vascular disease, hypertension and thrombosis associated with obesity.

21 September 2010 in Circulation
Verified
Journal Article
Open access
PDF file
TTTobias Traupe
Tobias Traupe
SGSteffen Gloekler
Steffen Gloekler
SMStefano F. de Marchi
Stefano F. de Marchi
GWGerald S. Werner
Gerald S. Werner
CSChristian Seiler
Christian Seiler

1 June 2003 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
MBMatthias Barton
Matthias Barton
RCRenata Carmona
Renata Carmona
JOJana Ortmann
Jana Ortmann
JKJose Krieger
Jose Krieger
TTTobias Traupe
Tobias Traupe

1 June 2007 in Hypertension
Verified
Journal Article
Closed access
TTTobias Traupe
Tobias Traupe
CSChristoph D. Stettler
Christoph D. Stettler
HLHuige Li
Huige Li
EHElvira Haas
Elvira Haas
IBIndranil Bhattacharya
Indranil Bhattacharya
MBMatthias Barton
Matthias Barton
This study investigated the contribution of estrogen receptors (ERs) α and β for epicardial coronary artery function, vascular NO bioactivity, and superoxide (O 2 − ) formation. Porcine coronary rings were suspended in organ chambers and precontracted with prostaglandin F 2α to determine direct effects of the selective ER agonists 4,4′,4″-(4-propyl-[ 1 H]pyrazole-1,3,5-triyl)tris-phenol (PPT) or 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) or the nonselective ER agonist 17β-estradiol. Indirect effects on contractility to U46619 and relaxation to bradykinin were assessed and effects on NO, nitrite, and O 2 − formation were measured in cultured cells. Within 5 minutes, selective ERα activation by PPT, but not 17β-estradiol or the ERβ agonist DPN, caused rapid, NO-dependent, and endothelium-dependent relaxation (49±5%; P <0.001 versus ethanol). PPT also caused sustained endothelium- and NO-independent vasodilation similar to 17β-estradiol after 60 minutes (72±3%; P <0.001 versus ethanol). DPN induced endothelium-dependent NO-independent relaxation via endothelium-dependent hyperpolarization (40±4%; P <0.01 versus ethanol). 17β-Estradiol and PPT, but not DPN, attenuated the responses to U46619 and bradykinin. All of the ER agonists increased NO and nitrite formation in vascular endothelial but not smooth muscle cells and attenuated vascular smooth muscle cell O 2 − formation ( P <0.001). ERα activation had the most potent effects on both nitrite formation and inhibiting O 2 − ( P <0.05). These data demonstrate novel and differential mechanisms by which ERα and ERβ activation control coronary artery vasoreactivity in males and females and regulate vascular NO and O 2 − formation. The findings indicate that coronary vascular effects of sex hormones differ with regard to affinity to ERα and ERβ, which will contribute to beneficial and adverse effects of hormone replacement therapy.

5 November 2009 in Heart
Verified
Journal Article
Closed access
PDF file
SGSteffen Gloekler
Steffen Gloekler
PMPascal Meier
Pascal Meier
SMStefano F de Marchi
Stefano F de Marchi
TRTobias Rutz
Tobias Rutz
TTTobias Traupe
Tobias Traupe
CSChristian Seiler
Christian Seiler
Background The efficacy of external counterpulsation (ECP) on coronary collateral growth has not been investigated in a randomised controlled study. Objective To test the hypothesis that ECP augments collateral function during a 1 min coronary balloon occlusion. Patients and methods Twenty patients with chronic stable coronary artery disease were studied. Before and after 30 h of randomly allocated ECP (20 90 min sessions over 4 weeks at 300 mm Hg inflation pressure) or sham ECP (same setting at 80 mm Hg inflation pressure), the invasive collateral flow index (CFI, no unit) was obtained in 34 vessels without coronary intervention. CFI was determined by the ratio of mean distal coronary occlusive pressure to mean aortic pressure with central venous pressure subtracted from both. Additionally, coronary collateral conductance (occlusive myocardial blood flow per aorto-coronary pressure drop) was determined by myocardial contrast echocardiography, and brachial artery flow-mediated dilatation was obtained. Results CFI changed from 0.125 (0.073; interquartile range) at baseline to 0.174 (0.104) at follow-up in the ECP group (p=0.006), and from 0.129 (0.122) to 0.111 (0.125) in the sham ECP group (p=0.14). Baseline to follow-up change of coronary collateral conductance was from 0.365 (0.268) to 0.568 (0.585) ml/min/100 mm Hg in the ECP group (p=0.072), and from 0.229 (0.212) to 0.305 (0.422) ml/min/100 mm Hg in the sham ECP group (p=0.45). There was a correlation between the flow-mediated dilatation change from baseline to follow-up and the corresponding CFI change (r=0.584, p=0.027). Conclusions ECP appears to be effective in promoting coronary collateral growth. The extent of collateral function improvement is related to the amount of improvement in the systemic endothelial function.